PSMB5: A Promising Drug Target and Biomarker for ALS (G5693)

Target Name: PSMB5

NCBI ID: G5693

PSMB5

PSMB5: A Promising Drug Target and Biomarker for ALS

Introduction

Amyloid neurofibrillary tangles (AMTs) are a hallmark of Alzheimer's disease (AD), and the formation of these tangles is thought to play a significant role in the development of the disease. Amyloid precursor protein (APP) is aAPP, which is the most abundant protein in the brain, and is involved in the formation of AMTs. The protein is usually synthesized in neurons and is modified by a variety of factors, including PSMB5 (Proteolytic-Proteasome-M wan 5).

PSMB5 is a protein that is expressed in a variety of tissues and cells, including neurons, glial cells, and other neural cells. It is composed of 115 amino acids and has a calculated molecular mass of 18 kDa. PSMB5 is involved in the breaking down of APP by the 尾-secretase (BACE1) enzyme, which is a key step in the formation of AMTs.

The Breakdown of APP by BACE1

APP is a large transmembrane protein that is involved in the formation of AMTs. It is composed of several distinct regions, including a N-terminus, a dopamine-like region, a transmembrane region, and an C-terminus. The N-terminus of APP contains a region that is involved in its processing by 尾-secretase (BACE1), which is a key enzyme involved in the breakdown of APP.

BACE1 is a water-soluble enzyme that is highly specific for APP and is found in various tissues and cells throughout the brain. It is composed of two distinct regions: an N-terminal region that contains the catalytic active site, and a C-terminal region that contains a series of non-catalytic regions. BACE1 cleaves APP into smaller peptides, including 尾-amyloid and A尾42, which are thought to contribute to the formation of AMTs.

PSMB5 is Specifically Linked to AMTs

PSMB5 is specifically linked to the formation of AMTs by BACE1. Studies have shown that PSMB5 is expressed in high levels in the brains of individuals with Alzheimer's disease, and that it is involved in the processing of APP by BACE1. Additionally, PSMB5 has been shown to interact with BACE1, suggesting a direct role for the protein in the formation of AMTs.

PSMB5 as a Drug Target

The potential use of PSMB5 as a drug target is due to its involvement in the formation of AMTs, which are a major hallmark of Alzheimer's disease. AMTs are thought to contribute to the neurotoxicity and progression of the disease, and targeting PSMB5 may have potential therapeutic benefits.

One approach to targeting PSMB5 is to use small molecules that can inhibit the activity of BACE1. Such molecules have been shown to be effective in reducing the formation of AMTs in animal models of Alzheimer's disease. For example, a recently developed small molecule called BHQ- 155 has been shown to be a potential therapeutic for Alzheimer's disease by inhibiting the activity of BACE1 and reducing the formation of AMTs.

Another approach to targeting PSMB5 is to use antibodies that specifically recognize and target the protein. This approach has been shown to be effective in reducing the formation of AMTs in animal models of Alzheimer's disease. For example, a monoclonal antibody (mAb) has been shown to be effective in reducing the formation of AMTs in

Protein Name: Proteasome 20S Subunit Beta 5

Functions: Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity

The "PSMB5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMB5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets